Nevro PE Ratio 2013-2022 | NVRO

Current and historical p/e ratio for Nevro (NVRO) from 2013 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Nevro PE ratio as of September 23, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Nevro PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-09-23 43.73 0.00
2022-06-30 43.83 $-3.99 0.00
2022-03-31 72.33 $-3.90 0.00
2021-12-31 81.07 $-3.77 0.00
2021-09-30 116.38 $-3.12 0.00
2021-06-30 165.79 $-1.97 0.00
2021-03-31 139.50 $-2.56 0.00
2020-12-31 173.10 $-2.49 0.00
2020-09-30 139.30 $-2.72 0.00
2020-06-30 119.47 $-3.01 0.00
2020-03-31 99.98 $-2.71 0.00
2019-12-31 117.54 $-3.38 0.00
2019-09-30 85.97 $-3.26 0.00
2019-06-30 64.83 $-3.05 0.00
2019-03-31 62.51 $-2.49 0.00
2018-12-31 38.89 $-1.63 0.00
2018-09-30 57.00 $-1.46 0.00
2018-06-30 79.85 $-1.30 0.00
2018-03-31 86.67 $-1.35 0.00
2017-12-31 69.04 $-1.26 0.00
2017-09-30 90.88 $-1.45 0.00
2017-06-30 74.43 $-1.38 0.00
2017-03-31 93.70 $-1.29 0.00
2016-12-31 72.66 $-1.12 0.00
2016-09-30 104.39 $-1.29 0.00
2016-06-30 73.76 $-1.85 0.00
2016-03-31 56.26 $-2.31 0.00
2015-12-31 67.51 $-2.57 0.00
2015-09-30 46.39 $-2.63 0.00
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.548B $0.387B
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $204.040B 20.78
Edwards Lifesciences (EW) United States $52.534B 37.17
Alcon (ALC) Switzerland $29.415B 24.91
STERIS (STE) Ireland $16.731B 20.78
Teleflex (TFX) United States $9.732B 15.51
Fresenius Medical Care AG KGaA (FMS) Germany $8.433B 7.78
Penumbra (PEN) United States $7.007B 840.64
Globus Medical (GMED) United States $5.801B 29.59
Glaukos (GKOS) United States $2.385B 0.00
Integer Holdings (ITGR) United States $2.051B 16.04
Paragon 28 (FNA) United States $1.343B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.035B 15.85
Artivion (AORT) United States $0.537B 51.19